Intensification of the Conditioning Regimen for Patients with high-risk AML and MDS: 3 year Experience of using an188 Re — Labelled anti — CD 66 Monoclonal Antibody

[1]  S. Reske.  Recent advances in bone marrow scanning , 2005, European Journal of Nuclear Medicine.

[2]  F. F. Knapp,et al.  The continuing important role of radionuclide generator systems for nuclear medicine , 1994, European Journal of Nuclear Medicine.

[3]  R. DeJager,et al.  Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies , 1994, European Journal of Nuclear Medicine.

[4]  F. Buchegger,et al.  Expression of nonspecific cross-reacting antigen species in myeloid leukemic patients and healthy subjects , 1989, Blut.

[5]  P. Schubiger,et al.  Assessment of the binding properties of Granuloszint , 2004, European Journal of Nuclear Medicine.

[6]  G. Hale,et al.  CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells , 2000, Bone Marrow Transplantation.

[7]  J. Nomdedéu,et al.  CD66 expression in acute leukaemia , 2000, Annals of Hematology.

[8]  G. Glatting,et al.  Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  R. Gray,et al.  A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial , 1999, British journal of haematology.

[10]  G. Glatting,et al.  Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia , 1999, European Journal of Nuclear Medicine.

[11]  I. Bernstein,et al.  Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome , 1999 .

[12]  T. Klingebiel,et al.  Transplantation of Megadoses of Purified Haploidentical Stem Cells , 1999, Annals of the New York Academy of Sciences.

[13]  M. Horowitz,et al.  Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. , 1998, Blood.

[14]  J. Treleaven,et al.  Clinical Practice of Stem-Cell Transplantation , 1998 .

[15]  F. Ferrara,et al.  CD66c antigen expression is myeloid restricted in normal bone marrow but is a common feature of CD10+ early-B-cell malignancies. , 1998, Tissue antigens.

[16]  C Anasetti,et al.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.

[17]  S. Mackinnon,et al.  T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. , 1998, Blood.

[18]  Wendy S. Becker,et al.  Overcoming the nephrotoxicity of radiometal‐labeled immunoconjugates , 1997, Cancer.

[19]  E. Cohen,et al.  Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation , 1997, Bone Marrow Transplantation.

[20]  M. Labopin,et al.  Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 1997, Blood.

[21]  P. Price,et al.  Important advances in oncology 1996 , 1997 .

[22]  J P Klein,et al.  Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[24]  C. Bloomfield,et al.  Clinical significance of cytogenetics in acute myeloid leukemia. , 1997, Seminars in oncology.

[25]  F. Appelbaum.  Allogeneic hematopoietic stem cell transplantation for acute leukemia. , 1997, Seminars in oncology.

[26]  S. Larson,et al.  Bone marrow dosimetry: regional variability of marrow-localizing antibody. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  M G Stabin,et al.  MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  R. Miralbell,et al.  Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Roberson,et al.  Experimental radioimmunotherapy: biological effectiveness and comparison with external beam radiation. , 1996, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[30]  M. Wannenmacher,et al.  Systemic Radiotherapy with Monoclonal Antibodies , 1996, Recent Results in Cancer Research.

[31]  J. Klein,et al.  Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. , 1995, Bone marrow transplantation.

[32]  H. Heimpel,et al.  In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate. , 1995, Bone marrow transplantation.

[33]  H. Heimpel,et al.  In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. , 1995, Bone marrow transplantation.

[34]  S. A. Bush,et al.  Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. , 1995, Blood.

[35]  C. Lawton,et al.  Bone marrow transplant nephropathy: radiation nephritis revisited. , 1995, Nephron.

[36]  R. Zager.  Acute renal failure in the setting of bone marrow transplatation , 1994 .

[37]  M. Paller.  Bone marrow transplantation nephropathy. , 1994, Journal of Laboratory and Clinical Medicine.

[38]  H. Waldmann,et al.  T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. , 1994, Bone marrow transplantation.

[39]  Wendy S. Becker,et al.  The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. , 1994, Seminars in nuclear medicine.

[40]  F. Appelbaum,et al.  Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. , 1993, Blood.

[41]  G Sgouros,et al.  Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  D. Mason,et al.  Immunohistological patterns of myeloid antigens: tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66 and CD67 , 1993, British journal of haematology.

[43]  I. Bernstein,et al.  Radiolabeled antibody therapy of lymphoma. , 1993, Cancer treatment and research.

[44]  I. Bernstein,et al.  THE USE OF RADIOLABELED ANTI‐CD33 ANTIBODY TO AUGMENT MARROW IRRADIATION PRIOR TO MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA , 1992, Transplantation.

[45]  A. Rimm,et al.  Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. , 1992, Blood.

[46]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[47]  J. Eary,et al.  Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. , 1991, Blood.

[48]  C. Lawton,et al.  Late renal dysfunction in adult survivors of bone marrow transplantation , 1991, Cancer.

[49]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[50]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. , 1991, Blood.

[51]  J. Gribben,et al.  Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. , 1991, Blood.

[52]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. , 1990, Blood.

[53]  G. Lucarelli,et al.  Bone marrow transplantation in patients with thalassemia. , 1990, The New England journal of medicine.

[54]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[55]  I. Bernstein,et al.  Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen. , 1990, Journal of the National Cancer Institute.

[56]  S. Reske,et al.  RADIOIMMUNOIMAGING FOR DIAGNOSIS OF BONE MARROW INVOLVEMENT IN BREAST CANCER AND MALIGNANT LYMPHOMA , 1989, The Lancet.

[57]  F. Appelbaum,et al.  Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  S. Sallan,et al.  Intravascular hemolysis and renal insufficiency after bone marrow transplantation , 1988 .

[59]  K. Sullivan,et al.  The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. , 1987, Bone marrow transplantation.

[60]  A. Harłozińska,et al.  Non-specific cross-reacting antigen (NCA) in individual maturation stages of myelocytic cell series. , 1985, British Journal of Cancer.

[61]  P. Neiman,et al.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. , 1977, Blood.

[62]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.